Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Acumen Pharmaceuticals ( (ABOS) ) has shared an update.
On May 13, 2025, Acumen Pharmaceuticals reported its first quarter financial results, highlighting a cash balance of $197.9 million as of March 31, 2025, which is expected to support operations into early 2027. The company is progressing with its Phase 2 ALTITUDE-AD study investigating sabirnetug for early Alzheimer’s disease, with topline results anticipated in late 2026. Acumen’s recent presentations at major conferences have emphasized the interest in sabirnetug’s selectivity for toxic amyloid beta oligomers, and the company’s increased R&D expenses reflect its commitment to advancing this promising therapeutic.
The most recent analyst rating on (ABOS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Acumen Pharmaceuticals stock, see the ABOS Stock Forecast page.
Spark’s Take on ABOS Stock
According to Spark, TipRanks’ AI Analyst, ABOS is a Underperform.
Acumen Pharmaceuticals has significant financial challenges with no revenue and increasing losses, heavily impacting its stock score. The completion of a key clinical trial phase is a positive, but technical indicators show bearish sentiment. Valuation metrics are unfavorable with ongoing losses. While cash reserves provide short-term financial stability, the company’s financial health and market sentiment necessitate significant improvements to achieve a higher stock score.
To see Spark’s full report on ABOS stock, click here.
More about Acumen Pharmaceuticals
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease. The company is advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody, in a Phase 2 clinical trial named ALTITUDE-AD for early symptomatic Alzheimer’s disease patients.
Average Trading Volume: 221,203
Technical Sentiment Signal: Sell
Current Market Cap: $63.6M
See more insights into ABOS stock on TipRanks’ Stock Analysis page.